Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. (APVO): 8 pipeline candidates · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.6 months
D/E 0.71 · 0% dilution
Lead: Phase 1
8 candidates
N/A
N/A
A transparent, data-derived signal for Aptevo Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.7M
Cash
$14.5M
Quarterly Burn
$8.0M
Runway
5.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| ALG.APV-527 | Phase 1 |
| apvo442 | Preclinical |
| apvo451 | Preclinical |
| apvo452 | Preclinical |
| apvo455 | Preclinical |
| apvo603 | Preclinical |
| apvo711 | Preclinical |
| mipletamig | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$185K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 25,426 | $109K |
| geode capital management, llc | 13,337 | $57K |
| vanguard fiduciary trust co | 4,142 | $18K |
| osaic holdings, inc. | 360 | $2K |
| gsa capital partners llp | 19,638 | $84 |
| danske bank a/s | 1 | $4 |
Frequently asked questions
How many drug candidates are in Aptevo Therapeutics Inc.'s pipeline?
Aptevo Therapeutics Inc. (APVO) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aptevo Therapeutics Inc.'s lead drug candidate?
Aptevo Therapeutics Inc.'s most advanced tracked candidate is ALG.APV-527 (Phase 1) for multiple solid tumor types.
What is Aptevo Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aptevo Therapeutics Inc. has approximately 5.6 months of cash runway.
What is Aptevo Therapeutics Inc.'s market capitalization?
Aptevo Therapeutics Inc.'s market capitalization is approximately $5.7M.
Who is the CEO of Aptevo Therapeutics Inc.?
Mr. Jeffrey G. Lamothe CA is the chief executive officer of Aptevo Therapeutics Inc. (APVO).
Get the full picture on Aptevo Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.